Back

Precision Diagnosis and Disease Biology of TGCT Establishing the Rationale for CSF1R Targeting

In this videobased module expert faculty reviews the clinical presentation diagnosis disease biology and multidisciplinary management of tenosynovial giant cell tumor TGCT a rare benign but locally aggressive synovial neoplasm that can cause substantial pain swelling stiffness recurrent effusions and functional impairment The activity distinguishes localized from diffusetype TGCT including differences in growth patterns recurrence risk and the limitations of surgery in infiltrative disease It also examines the roles of MRI CT and pathology in confirming the diagnosis defining disease extent identifying bone involvement and excluding malignant mimics In addition the faculty explains how CSF1 overexpression and recruitment of CSF1Rexpressing inflammatory cells contribute to tumor growth and symptom burden providing the biologic rationale for CSF1Rdirected therapy These concepts are important for improving early recognition referral to experienced multidisciplinary teams and individualized treatment decisions that balance disease control procedural morbidity symptom relief and preservation of joint function

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

ABIM — Medical KnowledgeUp to 0.5 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • includes Online course / module
  • Credit · Up to 0.5 credits
  • MOC · Up to 0.5 points
  • Commercial Support
  • Released
    Aug 7, 2026
  • Last day to claim credit
    Feb 7, 2027 4 months left